Use of PD-L1 Low Expression Status to Select Subjects for Cancer Immunotherapy
OwnerElizabeth EVANS, Maurice ZAUDERER +1inventors
InventorsElizabeth EVANS, Maurice ZAUDERER, Terry FISHER
Life of this patent
Estimating the term…
Abstract
The disclosure relates to methods for treating cancer or selecting subjects for cancer treatment using low PD-L1 expression as a patient biomarker prior to treatment.
Claims37
A method of selecting subjects having or suspected of having cancer for treatment with an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immune modulating therapy, preferably at least one immune checkpoint inhibitor, which comprises
- (a) determining PD-L1 expression levels in tumor tissue or cancerous cells of a subject;
- and
- (b) selecting the subject for treatment if
- (i) the tumor tissue is identified as having a combined positive score (CPS) of <25 or a tumor proportion score (TPS) ranging from <50% to <80% for PD-L1 expression, or
- (ii) the cancerous cells are identified as having a TPS ranging from <50% to <80% for PD-L1 expression.
A method for treating, inhibiting, delaying, or reducing malignant cell growth in a subject with cancer, comprising:
- (a) determining PD-L1 expression levels in tumor tissue or cancerous cells of the subject;
- and
- (b) administering to the subject an effective amount of an isolated antibody or antigen-binding fragment thereof that specifically binds to semaphorin-4D (SEMA4D) and an effective amount of at least one other immune modulating therapy, preferably at least one immune checkpoint inhibitor, if the tumor tissue or cells are identified as having either or both of a combined positive score (CPS) of <25 for PD-L1 expression or a tumor proportion score (TPS) ranging from <50% to <80%, thereby treating the subject.
A method of treating cancer in a human patient identified as having a tumor with low PD-L1 expression which comprises administering to the patient, as combination immunotherapy,
- (a) an anti-semaphorin-4D (SEMA4D) antibody, or an antigen binding fragment thereof, and
- (b) an immune checkpoint inhibitor,
- wherein the tumor has a combined positive score (CPS) of <25 before the immune checkpoint inhibitor is administered.
A method of treating cancer in a human patient identified as having a tumor or cancerous cells with low PD-L1 expression which comprises administering to the patient, as combination immunotherapy,
- (a) an anti-semaphorin-4D (SEMA4D) antibody, or an antigen binding fragment thereof, and
- (b) an immune checkpoint inhibitor,
- wherein the tumor has, or said cancerous cells have, a total proportion score (TPS) ranging from <50% to <80% before the immune checkpoint inhibitor is administered.
Dependencies are inferred from the claim text.